Business Description
Sopharma Trading AD
NAICS : 423450
SIC : 2834
ISIN : BG1100086070
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | 0.19 | |||||
Debt-to-Equity | 2 | |||||
Debt-to-EBITDA | 3.54 | |||||
Interest Coverage | 5.42 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.99 | |||||
Beneish M-Score | -2.21 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.1 | |||||
3-Year EBITDA Growth Rate | 24.7 | |||||
3-Year EPS without NRI Growth Rate | 35.6 | |||||
3-Year Book Growth Rate | 17 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 71.5 | |||||
9-Day RSI | 61.92 | |||||
14-Day RSI | 59.19 | |||||
6-1 Month Momentum % | -2.5 | |||||
12-1 Month Momentum % | -2.5 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.13 | |||||
Quick Ratio | 0.62 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 51.91 | |||||
Days Sales Outstanding | 48.26 | |||||
Days Payable | 38.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 0.35 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 11.47 | |||||
Operating Margin % | 2.79 | |||||
Net Margin % | 1.83 | |||||
FCF Margin % | -0.03 | |||||
ROE % | 26.38 | |||||
ROA % | 4.94 | |||||
ROIC % | 10.6 | |||||
ROC (Joel Greenblatt) % | 13.95 | |||||
ROCE % | 21.23 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 6.48 | |||||
Forward PE Ratio | 5.36 | |||||
PE Ratio without NRI | 6.37 | |||||
Shiller PE Ratio | 13.15 | |||||
Price-to-Owner-Earnings | 3.77 | |||||
PEG Ratio | 0.27 | |||||
PS Ratio | 0.12 | |||||
PB Ratio | 1.48 | |||||
Price-to-Tangible-Book | 2.11 | |||||
Price-to-Operating-Cash-Flow | 13.41 | |||||
EV-to-EBIT | 10.51 | |||||
EV-to-EBITDA | 6.07 | |||||
EV-to-Forward-EBITDA | 5.14 | |||||
EV-to-Revenue | 0.27 | |||||
EV-to-Forward-Revenue | 0.24 | |||||
EV-to-FCF | -999.77 | |||||
Price-to-DCF (Earnings Based) | 0.49 | |||||
Price-to-Median-PS-Value | 0.45 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.29 | |||||
Price-to-Graham-Number | 0.77 | |||||
Earnings Yield (Greenblatt) % | 9.51 | |||||
FCF Yield % | -0.23 | |||||
Forward Rate of Return (Yacktman) % | -35.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Sopharma Trading AD Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil лв) | 1,722.784 | ||
EPS (TTM) (лв) | 0.911 | ||
Beta | 0 | ||
Volatility % | 17.86 | ||
14-Day RSI | 59.19 | ||
14-Day ATR (лв) | 0.035546 | ||
20-Day SMA (лв) | 5.8825 | ||
12-1 Month Momentum % | -2.5 | ||
52-Week Range (лв) | 5.5 - 6.75 | ||
Shares Outstanding (Mil) | 34.28 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Sopharma Trading AD Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Sopharma Trading AD Stock Events
Event | Date | Price(лв) | ||
---|---|---|---|---|
No Event Data |
Sopharma Trading AD Frequently Asked Questions
What is Sopharma Trading AD(XBUL:SFT)'s stock price today?
When is next earnings date of Sopharma Trading AD(XBUL:SFT)?
Does Sopharma Trading AD(XBUL:SFT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |